CCA
CRXTW

Cruiser Capital Advisors’s Clarus Therapeutics Holdings, Inc. Warrants CRXTW Stock Holding History

Cruiser Capital Advisors’s Portfolio CRXTW Stock Details CRXTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-19,700
Closed -$11K – 61
2021
Q1 		$11K Buy
+19,700
New +$15.8K 0.01% 48

Other funds holding CRXTW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return

Cruiser Capital Advisors's CRXTW Position: Q2 2021 in Review

Cruiser Capital Advisors sold out of Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) in Q2 2021, closing a stake of 19,700 shares — an estimated $11K sold.

Cruiser Capital Advisors first reported a position in CRXTW in Q1 2021 and held it in 1 quarter. The position peaked at $11K in Q1 2021. 22 funds tracked by Wall St. Rank hold CRXTW as of Q2 2021.

  • Cruiser Capital Advisors reported no remaining Clarus Therapeutics Holdings, Inc. Warrants position as of Q2 2021 after selling out during the quarter.
  • Cruiser Capital Advisors sold 19,700 Clarus Therapeutics Holdings, Inc. Warrants shares in Q2 2021, an estimated $11K.
  • Cruiser Capital Advisors first reported a position in Clarus Therapeutics Holdings, Inc. Warrants in Q1 2021 and held it in 1 quarter.
  • Cruiser Capital Advisors's Clarus Therapeutics Holdings, Inc. Warrants position peaked at $11K in Q1 2021.
  • 22 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Warrants as of Q2 2021.

Based on Cruiser Capital Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.